SQLite Web: event_store.db

Update row 61991 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:3e23c1fbf8bad3e3","evidence_event_ids":["evt_034bd9ac8af6"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt","company":"Xilio Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt","article_chars":1643,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_ef577fe7f5938d60","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt","content_type":"text/plain","enriched_at":"2026-04-17T03:37:36.950417+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt","source_event_id":"evt_034bd9ac8af6","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"13c085580dcc33e2","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-15","2026-04-16","2026-04-17","2027-04-15","2028-04-15","2029-04-15"],"entities":[{"asset_class":"equity","name":"Xilio Therapeutics, Inc.","relevance":"high","symbol":"XLO","type":"issuer"},{"asset_class":"person","name":"Cheryl R. Blanchard","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"person","name":"Elana Brockmann","relevance":"low","symbol":"","type":"attorney_in_fact"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; no prior holdings/transactions are included to compare against.","The filing text excerpt does not explicitly state whether this is the only reported transaction in the Form 4 beyond the single ownership.xml item shown.","No explicit disclosure of whether the option is non-qualified or incentive stock option is included in the provided text."],"key_facts":["SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4)","Issuer: Xilio Therapeutics, Inc. (XLO)","Reporting person: Cheryl R. Blanchard (OWNER DATA: COMPANY CONFORMED NAME: Blanchard Cheryl R)","Filed as of date: 2026-04-16 (FILED AS OF DATE: 20260416)","Conformed period of report: 2026-04-15 (CONFORMED PERIOD OF REPORT: 20260415)","Transaction type/description includes: \"Stock Option (right to buy)\"","Option grant date: 2026-04-15 (\"The option was granted on April 15, 2026\")","Vesting: three equal installments on April 15, 2027; April 15, 2028; and April 15, 2029","Condition: vesting is subject to the reporting person\u2019s continued service through the applicable vesting date"],"numeric_claims":[{"label":"Option strike/price (as shown)","value":"8.40"},{"label":"Option quantity (as shown)","value":"10000"},{"label":"Vesting installments","value":"3"},{"label":"Grant date","value":"2026-04-15"},{"label":"Vesting dates (count)","value":"3"}],"primary_claim":"Form 4 for Xilio Therapeutics, Inc. (XLO) was filed on 2026-04-16 and discloses a stock option grant to Cheryl R. Blanchard with vesting on April 15 of 2027, 2028, and 2029 (subject to continued service).","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Xilio Therapeutics, Inc. (XLO) filed a Form 4 on 2026-04-16 reporting a stock option grant to reporting person Cheryl R. Blanchard. The option was granted on 2026-04-15 and is described as vesting in three equal annual installments from 2027 through 2029, subject to continued service.","topics":["SEC Form 4","insider transaction","stock option grant","vesting schedule","continued service condition"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Xilio Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"XLO","tickers":["XLO"],"title":"XLO filed 4","url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-159316.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel